AnaptysBio, Inc. (ANAB) shares rallied 30.5% in the last trading session to close at $16.15. This move can be attributable to notable volume with a higher number of shares being traded than in a ...

ANAB will conduct ongoing workshops and webinars regarding the requirements under ANSI/ASTM E2659-24, and encourages certificate issuers to analyze and familiarize themselves with the requirements ...

Has AnaptysBio, Inc. (ANAB) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.

ANAB remains risky despite new clinical data and partnerships; past successes haven't been replicated, and management's transparency issues raise concerns. The recent deal for Imsidolimab reflects ...

ANAB will conduct ongoing workshops and webinars regarding the requirements under ANSI/ASTM E2659-24, and encourages certificate issuers to analyze and familiarize themselves with the requirements of ...

Shares of AnaptysBio (NASDAQ:ANAB) climbed ~12% in the premarket on Wednesday after the biotech said its lead asset, rosnilimab, reached the main goals in a mid-stage trial targeted at the ...

JPMorgan raised the firm’s price target on AnaptysBio (ANAB) to $42 from $36 and keeps an Overweight rating on the shares. The firm updated models in the Smid-cap biotechnology group.

AnaptysBio (NASDAQ:ANAB – Get Free Report) will likely be releasing its earnings data before the market opens on Monday, March 10th. Analysts expect AnaptysBio to post earnings of ($1.55 ...

Guggenheim raised the firm’s price target on AnaptysBio (ANAB) to $52 from $36 and keeps a Buy rating on the shares following the company’s Q4 update. The firm is “encouraged” by the ...